Legend Biotech Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ying Huang
- Full Time Employees
- 2,600
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2101 Cottontail Lane Somerset NJ United States of America 08873
- IPO Date
- Jun 5, 2020
- CIK
- 0001801198
- Website
- legendbiotech.com
- Similar Companies
- Business
- Legend Biotech Corporation Legend Biotech Corporation (LEGN) is a global commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of cell therapies targeting oncology indications including hematologic malignancies such as multiple myeloma and solid tumors. Founded in 2014 and headquartered in Somerset, New Jersey, the company operates facilities across the United States including Piscataway and a new R&D center in Philadelphia, as well as in Nanjing, China; Dublin, Ireland; and Ghent, Belgium. Its lead product, CARVYKTI (ciltacabtagene autoleucel; cilta-cel), an autologous BCMA-targeted CAR-T therapy developed and commercialized in partnership with Janssen Biotech, Inc., treats relapsed or refractory multiple myeloma and generates primary revenue through license and collaboration agreements predominantly from the United States; the company also advances a pipeline of investigational autologous CAR-T candidates for non-Hodgkin lymphoma, acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, small cell lung, and non-small cell lung cancers, alongside allogeneic CAR-NK, CAR-γδ T, and non-gene-editing CAR technologies. Recent developments include the official opening of a state-of-the-art cell therapy R&D facility in Philadelphia in November 2025, plans to double CARVYKTI manufacturing capacity in 2025 through new sites in Raritan, New Jersey, and Ghent, Belgium under agreements with Janssen and Novartis, a strategic partnership with Novartis announced in 2024 providing $100 million upfront for CAR-T candidates targeting solid tumors via the T-Charge platform with over $1 billion in potential milestones, and a collaboration with Multiply Labs to automate CAR-T manufacturing processes.
Legend Biotech Jumps 42% On New Data -- Here's What Comes Next
Dow, S&P 500 Hit Fresh Records After Market Rebound
Legend's experimental cell therapy shows promise in blood cancer patients
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use
Legend Biotech Announces Presentations at ASCO 2026
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript
Legend Biotech Q1 Earnings Call Highlights
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
Legend Biotech: Undervalued Leader In The CAR-T Race
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?
Why Legend Biotech Stock Crushed the Market on Monday
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Recommendation of “Moderate Buy” by Brokerages